Sputum culture and drug sensitivity testing outcome among X-pert MTB/Rif positive, rifampicin resistant sputa: A retrospective study - Not all rifampicin resistance is MDR.
Tshepong Hospital multidrug resistant (MDR) unit between April 2011 and February 2014. Rifampicin resistant (RR) tuberculosis (TB) on X-pert MTB/Rif is assumed a surrogate for MDR TB. Following a RR result, a second specimen is taken for confirmatory culture and drug susceptibility testing (DST). We compare the initial diagnostic X-pert MTB/RIF result to the confirmatory DST in a high HIV seroprevalence setting. We retrospectively reviewed records analyzing demographics, HIV serostatus, prior TB treatments and DST results. Of 604 patients with X-pert MTB/RIF RR, 374(61.9%) had a DST and were included. The mean age was 36.9 years and 82% were HIV-infected. Following DST, MDR was confirmed in 49% and Rif mono-resistant (RMR) TB in 36%. Amongst RMR TB, 84% were HIV-infected and amongst those with CD4 < 50 versus those 50-350 cells/mm3 RMR TB was noted in 51% versus 33% (p = 0.012). Primary DR was diagnosed in 43% (61% MDR and 33% RMR). RR detected on a diagnostic X-pert MTB/Rif assay did not always predict MDR. RMR is emerging amongst those with HIV co - infection and low CD4 count (<50cells/mm3) and research is needed to reduce the number of drugs and treatment durations for RMR TB.